These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 25614144)
21. Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma. Zhang L; Gao Y; Li M; Xu C; Davis JD; Kanamaluru V; Lu Q CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):941-952. PubMed ID: 34313019 [TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Fasanmade AA; Adedokun OJ; Ford J; Hernandez D; Johanns J; Hu C; Davis HM; Zhou H Eur J Clin Pharmacol; 2009 Dec; 65(12):1211-28. PubMed ID: 19756557 [TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Hanzel J; Bukkems LH; Gecse KB; D'Haens GR; Mathôt RAA Aliment Pharmacol Ther; 2021 Nov; 54(10):1309-1319. PubMed ID: 34559426 [TBL] [Abstract][Full Text] [Related]
24. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies. Chua L; Friedrich S; Zhang XC Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075 [TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing. Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684 [TBL] [Abstract][Full Text] [Related]
27. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients. Shen T; James DE; Krueger KA Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis. Wei X; Gibiansky L; Wang Y; Fuh F; Erickson R; O'Byrne S; Tang MT J Clin Pharmacol; 2018 Mar; 58(3):386-398. PubMed ID: 29178491 [TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Fiedler-Kelly JB; Cohen-Barak O; Morris DN; Ludwig E; Rasamoelisolo M; Shen H; Levi M Br J Clin Pharmacol; 2019 Dec; 85(12):2721-2733. PubMed ID: 31418911 [TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition Model-Support for a Biologics License Application Submission: Part I. Martinez JM; Brunet A; Hurbin F; DiCioccio AT; Rauch C; Fabre D Clin Pharmacokinet; 2019 Jan; 58(1):101-113. PubMed ID: 29725996 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials. Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537 [TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations. Bihorel S; Fiedler-Kelly J; Ludwig E; Sloan-Lancaster J; Raddad E AAPS J; 2014 Sep; 16(5):1009-17. PubMed ID: 24912797 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus. Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033 [TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin Chen X; Li C; Ewesuedo R; Yin D Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088 [TBL] [Abstract][Full Text] [Related]
36. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis. Xu Y; Hu C; Chen Y; Miao X; Adedokun OJ; Xu Z; Sharma A; Zhou H J Clin Pharmacol; 2020 Jul; 60(7):889-902. PubMed ID: 32026499 [TBL] [Abstract][Full Text] [Related]
37. Integrated Population Pharmacokinetic Analysis of Ustekinumab Across Multiple Immune-Mediated Inflammatory Disease Populations and Healthy Subjects. Shao J; Xu Z; Xu Y Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):537-548. PubMed ID: 35442011 [TBL] [Abstract][Full Text] [Related]
38. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials. Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118 [TBL] [Abstract][Full Text] [Related]
39. A Phase 1 Study of KHK4083: A Single-Blind, Randomized, Placebo-Controlled Single-Ascending-Dose Study in Healthy Adults and an Open-Label Multiple-Dose Study in Patients With Ulcerative Colitis. Furihata K; Ishiguro Y; Yoshimura N; Ito H; Katsushima S; Kaneko E; Shimabe M; Mukai M; Watanabe R; Morishige T Clin Pharmacol Drug Dev; 2021 Aug; 10(8):870-883. PubMed ID: 33512065 [TBL] [Abstract][Full Text] [Related]
40. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials. Suleiman AA; Khatri A; Minocha M; Othman AA Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]